# Commercialization of ALM-488 for Highlighting Nerves During Image Guided Surgeries

> **NIH NIH SB1** · ALUME BIOSCIENCES, INC. · 2022 · $1,670,941

## Abstract

PROJECT SUMMARY
Fundamental to the goals of surgery are functional preservation of critical nerves and minimization of post-
operative patient morbidity. Unfortunately, inadvertent nerve injury during surgery continues to be a major cause
of post-surgical patient morbidity due to the inability of surgeons to visualize nerves during surgery. Nerve injury
during surgery can lead to chronic pain, numbness, permanent paralysis, incontinence, and erectile dysfunction.
Current nerve identification strategies utilize non-quantifiable criteria such as anatomy, texture, color, and
relationship to surrounding structures to distinguish nerves from non-nerve tissues. In instances of trauma, tumor
invasion, or infection, nerve identification using the above criteria is especially challenging and often fails to
prevent nerve damage. Using white light reflectance, which is the standard mode of illumination in operating
rooms, the visual difference between small nerves and adjacent tissue can be imperceptible. There is an unmet
need to improve the intraoperative visualization of nerves to preserve nerve function and minimize patient
morbidity following surgery. There are currently no clinically approved agents that enhance nerve contrast during
surgery. Alume Biosciences has advanced a first-in-class IV-administered agent for nerve visualization. This
candidate, ALM-488, is a peptide dye conjugate that binds motor, sensory, and autonomic nerves in vivo and
enables nerve visualization with high nerve to non-nerve contrast with no inherent toxicity. ALM-488 is currently
being evaluated in a clinical trial in head and neck cancer surgery patients to establish safety and efficacy for
clinical use. In this CRP proposal, Alume proposes to accelerate ALM-488 towards a final NDA-enabling Phase
3 trial and commercialization by 1) manufacturing drug substance and drug product stability lots to satisfy NDA
requirements; 2) completing Phase 3-enabling toxicology studies; and 3) performing a U.S. market assessment
to inform market positioning. Alume anticipates that clinical translation of ALM-488 will be transformative for the
surgical field to prevent inadvertent injury during surgery and improve post-operative patient outcomes.

## Key facts

- **NIH application ID:** 10480219
- **Project number:** 1SB1NS127647-01
- **Recipient organization:** ALUME BIOSCIENCES, INC.
- **Principal Investigator:** Brett J. Berman
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,670,941
- **Award type:** 1
- **Project period:** 2022-09-15 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10480219

## Citation

> US National Institutes of Health, RePORTER application 10480219, Commercialization of ALM-488 for Highlighting Nerves During Image Guided Surgeries (1SB1NS127647-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10480219. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*